Nxera Pharma Co., Ltd.
4565.T
Get informed when a big investor buys or sells
+ FollowMarket Cap$113.01B
Close$
$-120.08
109.7% downside
Current Fair Value
109.7% downsideOvervalued by 109.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $113.01 Billion |
|---|---|
| Enterprise Value | $149.41 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-138.8 |
| Beta | 0.23 |
| Outstanding Shares | 91,375,778 |
Return
| Return on Equity | -12.16% |
|---|---|
| Return on Assets | -5.95% |
| Return on Invested Capital | -1.39% |
Valuation & Multiples
| P/E Ratio | -14.27 |
|---|---|
| PEG | 15.58 |
| Price to Sales | 3.36 |
| Price to Book Ratio | 1.75 |
| Enterprise Value to Revenue | 4.45 |
| Enterprise Value to EBIT | -92.42 |
| Enterprise Value to Net Income | -20 |
| Total Debt to Enterprise | 0.36 |
| Debt to Equity | 0.84 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 7, 2026
EPS Estimate
$-3.43
Average shareholder expectationRevenue Estimate
$8.48 B
Average shareholder expectationNext Earnings Call
Expected Date
October 30, 2026
EPS Estimate
$0.50
Average shareholder expectationRevenue Estimate
$8.18 B
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Nxera Pharma Co., Ltd.
322 employees
CEO: Christopher Cargill Nxera Pharma Co., Ltd., established in Tokyo, Japan, in 1990, is a biopharmaceutical enterprise focused on the discovery, development, and commercialization of pharmaceutical solutions. The company's operations extend across multiple int...